OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Endocrinology is 60. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
COVID-19 and diabetes mellitus: from pathophysiology to clinical management	619
Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure	429
Obesity and impaired metabolic health in patients with COVID-19	427
Global pandemics interconnected — obesity, impaired metabolic health and COVID-19	316
The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic	276
Exerkines in health, resilience and disease	275
Endocrine and metabolic link to coronavirus infection	254
Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?)	249
Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment	238
The role of sugar-sweetened beverages in the global epidemics of obesity and chronic diseases	237
Mitochondrial and metabolic dysfunction in ageing and age-related diseases	236
The burden and risks of emerging complications of diabetes mellitus	227
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus	218
Current understanding of the molecular and cellular pathology of diabetic retinopathy	214
Diet and exercise in the prevention and treatment of type 2 diabetes mellitus	209
Lipid and glucose metabolism in white adipocytes: pathways, dysfunction and therapeutics	199
Type 2 diabetes mellitus in older adults: clinical considerations and management	188
The health effects of vitamin D supplementation: evidence from human studies	182
Tracking placental development in health and disease	172
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus	167
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy	164
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus	162
GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease	161
Autophagy in metabolic disease and ageing	160
Endocrine toxicities of immune checkpoint inhibitors	160

Current practice in patients with differentiated thyroid cancer	150
Sexual dimorphism in cardiometabolic health: the role of adipose tissue, muscle and liver	147
Circadian rhythms and the gut microbiota: from the metabolic syndrome to cancer	146
Nearly a decade on — trends, risk factors and policy implications in global obesity	139
International consensus on the diagnosis and management of dumping syndrome	126
Will the COVID-19 pandemic worsen the obesity epidemic?	124
Environmental factors in declining human fertility	120
Metabolic regulation of kisspeptin — the link between energy balance and reproduction	113
Nuclear receptor crosstalk — defining the mechanisms for therapeutic innovation	112
Therapeutic opportunities for pancreatic β-cell ER stress in diabetes mellitus	106
Creatine metabolism: energy homeostasis, immunity and cancer biology	103
Clinical application of intermittent fasting for weight loss: progress and future directions	102
Exercise adaptations: molecular mechanisms and potential targets for therapeutic benefit	98
Paracetamol use during pregnancy — a call for precautionary action	92
The role of insufficient sleep and circadian misalignment in obesity	87
Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD	86
New insights into KATP channel gene mutations and neonatal diabetes mellitus	86
Metabolic pathways in obesity-related breast cancer	84
Emerging routes to the generation of functional β-cells for diabetes mellitus cell therapy	84
The evolving view of thermogenic adipocytes — ontogeny, niche and function	79
International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers	76
Macrophage functional diversity in NAFLD — more than inflammation	75
Epigenetic inheritance of polycystic ovary syndrome — challenges and opportunities for treatment	74
Tuning fatty acid oxidation in skeletal muscle with dietary fat and exercise	72
The importance of the RET gene in thyroid cancer and therapeutic implications	71
Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis	70
Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus	69
Novel therapies with precision mechanisms for type 2 diabetes mellitus	69
Brain insulin signalling in metabolic homeostasis and disease	68
Understanding the ever-changing incidence of thyroid cancer	67
Pathogenesis and treatment of primary aldosteronism	65
Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations	64
Clinical aspects of multiple endocrine neoplasia type 1	64
The physiological role of β-cell heterogeneity in pancreatic islet function	61
Metformin: update on mechanisms of action and repurposing potential	60
Functions of galanin, spexin and kisspeptin in metabolism, mood and behaviour	60
Cellular and molecular features of EDC exposure: consequences for the GnRH network	60